Projects funded by the NCN

Information on the principal investigator and host institution

Information of the project and the call

Keywords

Equipment

Delete all

Research of a new small-molecule 1,2,4-triazine derivative (MM-129) - assessment of anti-neoplastic activity and safety of use in an experimental model of colorectal carcinoma.

2018/31/B/NZ7/00875

Keywords:

1,2,4-triazines derivatives colon cancer Zebrafish mouse xenograft model

Descriptors:

  • NZ7_14: Pharmacy, pharmacotherapy, pharmacology

Panel:

NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology

Host institution :

Uniwersytet Medyczny w Białymstoku, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

woj. podlaskie

Other projects carried out by the institution 

Principal investigator (from the host institution):

prof. Dariusz Pawlak 

Number of co-investigators in the project: 10

Call: OPUS 16 - announced on 2018-09-14

Amount awarded: 1 434 320 PLN

Project start date (Y-m-d): 2019-06-28

Project end date (Y-m-d): 2022-12-27

Project duration:: 42 months (the same as in the proposal)

Project status: Project settled

Project description

Download the project description in a pdf file

Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Equipment purchased [PL]

  1. Inkubator CO2 z wyposażeniem (60 000 PLN)
  2. Cyfrowa kolorowa kamera mikroskopowa (80 000 PLN)
  3. System do obrazowania żeli i blotów z zestawem do elektroforezy i transferu (268 470 PLN)

Information in the final report

  • Publication in academic press/journals (4)
  • Articles in post-conference publications (6)
  1. Exploration of novel heterofused 1,2,4-triazine derivative in colorectal cancer
    Authors:
    Justyna Magdalena Hermanowicz, Anna Szymanowska, Beata Sieklucka, Robert Czarnomysy, Krystyna Pawlak, Anna Bielawska, Krzysztof Bielawski, Joanna Kalafut, Alicja Przybyszewska, Arkadiusz Surazynski, Adolfo Rivero-Muller, Mariusz Mojzych, Dariusz Pawlak
    Academic press:
    Journal of Enzyme Inhibition and Medicinal Chemistry (rok: 2021, tom: 36, strony: 535-348), Wydawca: Taylor & Francis Group
    Status:
    Published
    DOI:
    10.1080/14756366.2021.1879803 - link to the publication
  2. Important players in carcinogenesis as potential targets in cancer therapy: an update
    Authors:
    Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Dariusz Pawlak
    Academic press:
    Oncotarget (rok: 2020, tom: 11, strony: 3078-3101), Wydawca: eJournalPress
    Status:
    Published
    DOI:
    10.18632/oncotarget.27689 - link to the publication
  3. MM-129 as a novel inhibitor targeting PI3K/AKT/mTOR and PD-L1 in colorectal cancer.
    Authors:
    ermanowicz Justyna Magdalena, Pawlak Krystyna, Sieklucka Beata, Czarnomysy Robert, Kwiatkowska Iwona, Kazberuk Adam, Surażyński Arkadiusz, Mojzych Mariusz, Pawlak Dariusz.
    Academic press:
    Cancers (rok: 2021, tom: 13, strony: 3203), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers13133203 - link to the publication
  4. Preclinical toxicity and safety of MM-129 - first-in-class BTK/PD-L1 inhibitor as a potential candidate against colon cancer.
    Authors:
    Hermanowicz Justyna Magdalena, Kałaska Bartłomiej, Pawlak Krystyna, Sieklucka Beata, Mikłosz Joanna, Mojzych Mariusz, Pawlak Dariusz.
    Academic press:
    Pharmaceutics (rok: 2021, tom: 13, strony: 1222), Wydawca: MDPI
    Status:
    Published
    DOI:
    10.3390/pharmaceutics13081222 - link to the publication
  1. MM-129 as novel potential anticancer agent against colorectal cancer.
    Authors:
    Justyna Hermanowicz, Iwona Kwiatkowska, Arkadiusz Surażyński, Dariusz Pawlak
    Conference:
    ACCORD 2022. Interdisciplinary Conference on Drug Sciences "Synergy of interdisciplinary innovations" (rok: 2022, ), Wydawca: MDPI
    Data:
    konferencja 26-28 maj
    Status:
    Published
  2. MM-129 as a new potential candidate against colon cancer - assessment of toxicity.
    Authors:
    Justyna Hermanowicz, Iwona Kwiatkowska, Dariusz Pawlak
    Conference:
    10th Jubilee International Conference on Radiation in Various Fields of Research, Herceg Novi, Montenegro (rok: 2022, ), Wydawca: nie dotyczy
    Data:
    konferencja 13-17 czerwca
    Status:
    Published
  3. MM-129: a derivative with a dual mechanism of action as an innovative molecule with antitumor activity against colon cancer cells.
    Authors:
    Iwona Kwiatkowska, Justyna Hermanowicz, Robert Czarnomysy, Arkadiusz Surażyński, Dariusz Pawlak
    Conference:
    10th Jubilee International Conference on Radiation in Various Fields of Research, Herceg Novi, Montenegro (rok: 2022, ), Wydawca: nie dotyczy
    Data:
    konferencja 13-17 czerwca
    Status:
    Published
  4. Proapoptotic activity of MM-129 in experimental colon cancer models.
    Authors:
    Kwiatkowska Iwona, Hermanowicz Justyna, Czarnomysy Robert, Bielawska Anna, Mojzych Mariusz, Bielawski Krzysztof, Pawlak Dariusz.
    Conference:
    ACCORD 2022. Interdisciplinary Conference on Drug Sciences "Synergy of interdisciplinary innovations". (rok: 2022, ), Wydawca: MDPI
    Data:
    konferencja 26-28 maj
    Status:
    Published
  5. Synthesis and cellular effects of novel 1,2,4-triazine derivative in human colon cancer
    Authors:
    Justyna Magdalena Hermanowicz, Iwona Kwiatkowska, Krystyna Pawlak, Mariusz Mojzych, Anna Bielawska, Krzysztof Bielawski, Dariusz Pawlak
    Conference:
    X Konwersatorium Chemii Medycznej (rok: 2021, ), Wydawca: Polskie Towarzystwo Chemii Medycznej
    Data:
    konferencja 2021-09-3-5
    Status:
    Published
  6. Evaluation of the anticancer activities of novel 1,2,4-triazine sulfonamide derivative in colon cancer.
    Authors:
    Justyna Hermanowicz, Arkadiusz Surażyński, Hubert Klepacki, Dariusz Pawlak.
    Conference:
    New Trends in Polish and Global Pharmacy: Science, Business, and Modern Education. Poznań (rok: 2022, ), Wydawca: nie dotyczy
    Data:
    konferencja 29-30 września
    Status:
    Published

O Narodowym Centrum Nauki

Finansowanie nauki

Współpraca zagraniczna

Centrum prasowe

Deklaracja dostępności
Przetwarzanie danych osobowych
Polityka cookies

Partnerzy